Influence of CYP3A53 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia

• Published in: Journal of clinical pharmacy and therapeutics Vol. 41; no. 5; pp. 546 - 551
• Main Authors: Adeagbo, B. A., Bolaji, O. O., Olugbade, T. A., Durosinmi, M. A., Bolarinwa, R. A., Masimirembwa, C.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.10.2016; Hindawi Limited
• Subjects: ABCB1 C3435T; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - blood; Antineoplastic Agents - therapeutic use; ATP Binding Cassette Transporter, Sub-Family B - genetics; chronic myeloid leukaemia; CYP3A53; Cytochrome P-450 CYP3A - genetics; Female; genetic polymorphism; Genotype; Humans; imatinib; Imatinib Mesylate - blood; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Male; Middle Aged; Nigeria; Pharmacogenetics - methods; Polymorphism, Genetic - genetics; Young Adult; imatinib; genetic polymorphism; ABCB1 C3435T; CYP3A53; chronic myeloid leukaemia

Summary What is known and objective Imatinib mesylate is the first‐line drug for the treatment of Philadelphia/bcr‐abl positive chronic myeloid leukaemia (CML). It is known to be metabolized mostly by CYP3A4 and CYP3A5 isoforms while its efflux is mediated by the transporters ABCB1 and ABCG2. Geneti...